Held back by the poison pen, will Fullerton Health give IPO plans another shot?

SINGAPORE (Nov 25): If Fullerton’s IPO had gone ahead, it would have been one of the largest of the year. And, with an expected market value of more than $1.1 billion, it would have been a welcome addition to the burgeoning cluster of healthcare plays in the Singapore Exchange (SGX).

However, the registration – initially slated for Oct 10 – was put off after regulators sought additional information from the company.

See: Fullerton Health said to delay IPO after regulatory queries

---

Related Stories

• Southeast Asia raises only US$3 bil in total IPO capital so far in 2024, lowest in nine years: Deloitte
• Horizon Robotics’ shares jump 38% in HK after US$696 mil IPO
• Tokyo Metro shares ride high in trading debut after strong IPO

---